Advances in the treatment and prognosis of intrahepatic cholangiocarcinoma
10.3760/cma.j.cn112139-20250526-00275
- VernacularTitle:肝内胆管癌治疗与预后预测的研究进展
- Author:
Liangshuo HU
1
;
Yi LYU
;
Pawlik Timothy M.
;
Xufeng ZHANG
Author Information
1. 西安交通大学第一附属医院肝胆外科 精准外科与再生医学国家地方联合工程中心，西安 710061
- Publication Type:Journal Article
- Keywords:
Bile duct neoplasms;
Surgical procedures, operative;
Intrahepatic cholangiocarcinoma;
Systemic therapy;
Artificial intelligence
- From:
Chinese Journal of Surgery
2026;64(1):34-40
- CountryChina
- Language:Chinese
-
Abstract:
Intrahepatic cholangiocarcinoma (ICC) is a highly malignant primary tumor originating from the intrahepatic bile duct epithelium. Current clinical consensus emphasizes that early detection,timely diagnosis,and R0 resection (when feasible) are critical strategies for improving outcomes. Advances in surgical techniques and multidisciplinary approaches have facilitated precision medicine-guided systemic therapies,including adjuvant and neoadjuvant regimens. These interventions significantly delay postoperative recurrence and improve 5-year survival rates. Systemic treatments have also modestly enhanced prognoses for advanced ICC patients. Artificial intelligence-driven radiomics and deep learning technologies show substantial efficacy in ICC diagnosis,prognostic assessment,and lymph node metastasis prediction,advancing precision medicine applications. Despite these therapeutic advances,survival outcomes-particularly for advanced-stage ICC-remain suboptimal. Future efforts should prioritize molecular signature-guided therapies,novel combination regimens,and artificial intelligence-assisted comprehensive management to establish a molecularly driven precision treatment framework.
